Advanced

• Fortra announced the launch of its new Defense and Intelligence Unit (DIU) on April 16, 2026, from Minneapolis to deliver integrated cyber solutions to defense and national security organizations worldwide. • The unit focuses on cross-domain cyber innovation, AI-powered capabilities, and mission expertise for critical infrastructure and allied nations. • This development strengthens US cybersecurity posture amid rising global threats to defense sectors.

• NTT Research unveiled SaltGrain, a new data security suite designed to break the traditional all-or-nothing file-access model and enhance privacy protection. • The platform addresses existing cybersecurity gaps by enabling granular access control through advanced attribute-based encryption technology. • SaltGrain represents a significant advancement in data protection capabilities, offering enterprises more sophisticated control over sensitive information access and sharing.

• Thomas Jefferson University launched a multicenter clinical trial led by Manisha Verma, MD, and Victor Navarro, MD, at Jefferson Einstein Philadelphia Hospital to improve palliative care for advanced liver disease patients. • Advanced liver disease causes significant scarring and loss of function, leading to serious health challenges with limited quality-of-life support. • Funded by the Patient-Centered Outcomes Research Institute and published in JAMA Internal Medicine, the trial addresses a major care gap for ALD patients nationwide.

• A paralyzed man successfully controlled a robotic arm by using a neural interface device that relays signals from his brain to a computer, enabling him to grasp, move, and drop objects through thought alone. • The breakthrough demonstrates the practical application of brain-computer interface technology, allowing the patient to perform complex motor tasks that were previously impossible due to paralysis. • This advancement represents a significant milestone in neurotechnology and rehabilitation, offering hope for individuals with paralysis by restoring functional control of external robotic limbs through neural signals.

• The FDA granted accelerated approval to a novel immunotherapy combination for metastatic pancreatic cancer on March 21, 2026, based on Phase 2 trial data showing a 35% response rate. • The drug combination demonstrated a median overall survival of 14.2 months compared to 11.8 months with standard chemotherapy in the clinical trial of 280 patients. • Pancreatic cancer remains one of the deadliest cancers with a five-year survival rate below 12%, making this approval potentially significant for the estimated 64,000 Americans diagnosed annually.

• Advanced Machine Intelligence raised over $1 billion in a major funding round on March 16, 2026, targeting AI systems specialized in reasoning, planning, and world models. • Investors are shifting capital toward alternative AI architectures beyond traditional large language models, prioritizing deep tech with strategic advantages. • This deal highlights the growing emphasis on startups with access to computational power and proprietary data in the US venture market.